The place of clozapine in the treatment of schizophrenia;De plaats van clozapine bij de behandeling van schizofrenie

Tijdschrift voor Psychiatrie

Volumn 43, Issue 10, 2001, Pages 715-720

  Schulte, P F J ^a  

^a NONE   (Netherlands)

Author keywords

Adverse effects; Clozapine; Refractory schizophrenia

Indexed keywords

CLOZAPINE;

CARDIOMYOPATHY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; MORTALITY; MYOCARDITIS; REVIEW; SCHIZOPHRENIA;

EID: 0034769914     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States
2. Clozapine and myocarditis
3. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
4. Risperidone versus clozapine in treatment-resistant chronic schizophrenia. A randomized double-blind study
5. Reactie op 'koorts en leucocytose' als voorbijgaande bijwerking van clozapine
6. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
7. Clozapine and risperidone in chronic schizophrenia. Effects on symptoms, parkinsonian side effects, and neuroendocrine response
8. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients. A multicentre double-blind comparative study
9. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia
10. Treatment-resistant schizophrenia patients respond to clozapine after olanzapine non-response
11. Clozapine and sudden death (Brief)
12. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia
13. Treatment of tardive dyskinesia
14. Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories
15. Effects of clozapine for non-treatment-resistant patients with schizophrenia
16. Clozapine reduces violence and persistent aggression in schizophrenia
17. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medication
18. Tardive dystonia
19. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
20. Severe hyperglycemia associated with high doses of clozapine
21. Myocarditis and cardiomyopathy associated with clozapine
22. Diabetic ketoacidosis associated with clozapine treatment
23. Myocarditis and cardiomyopathy associated with clozapine use in the United States
24. Cardiomyopathy associated with clozapine
25. Integrating pharmacological and psychosocial treatments for schizophrenia
26. Clozapine decreases smoking in patients with chronic schizophrenia
27. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
28. Reducing suicide risk in schizophrenia. Focus on the role of clozapine
29. Effects of six months clozapine treatment on the quality of life of chronic schizophrenic patients
30. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
31. Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients
32. Diabetes mellitus in schizophrenic patients
33. Active monitoring of 12.760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance
34. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects
35. Plasma clozapine concentrations predict clinical response in treatmentresistant schizophrenia
36. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years
37. Atypical antipsychotics: Are some more atypical than others?
38. Medication continuation and compliance. A comparison of patients treated with clozapine and haloperidol
39. Does participation in psychosocial treatment augment the benefit of clozapine?
40. Pharmacogenetics and antipsychotic drugs
41. Clozapine plasma levels and convulsions
42. The effects of clozapine on aggression and substance abuse in schizophrenic patients
43. Mortality in current and former users of clozapine
44. Clozapine and sudden death (Brief)
45. Subjective experiences of clozapine treatment by patients with chronic schizophrenia
46. Risperidone in treatment-refractory schizophrenia
47. Motivation-based assessment and treatment of substance abuse in patients with schizophrenia
48. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder. A retrospective survey